These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 15686466)

  • 1. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
    Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
    Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
    Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
    Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
    Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural history of GATA1 mutations in Down syndrome.
    Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
    Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
    Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
    Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
    Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
    Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
    Vyas P; Roberts I
    Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
    Mundschau G; Gurbuxani S; Gamis AS; Greene ME; Arceci RJ; Crispino JD
    Blood; 2003 Jun; 101(11):4298-300. PubMed ID: 12560215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
    Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
    Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA1-related leukaemias.
    Shimizu R; Engel JD; Yamamoto M
    Nat Rev Cancer; 2008 Apr; 8(4):279-87. PubMed ID: 18354416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Origins of leukaemia in children with Down syndrome.
    Hitzler JK; Zipursky A
    Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutations of erythroid/megakaryocytic transcription factor GATA-1 and leukemia in childhood].
    Ito E
    Rinsho Ketsueki; 2004 Feb; 45(2):108-14. PubMed ID: 15045818
    [No Abstract]   [Full Text] [Related]  

  • 20. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
    Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
    An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.